Balyasny Asset Management
PLRX icon

Balyasny Asset Management’s Pliant Therapeutics PLRX Stock Holding History

Balyasny Asset Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-31,910
Closed -$343K – 3068
2024
Q2 		$343K Buy
+31,910
New +$411K ﹤0.01% 2190
2024
Q1 		– Sell
-37,143
Closed -$673K – 3006
2023
Q4 		$673K Buy
+37,143
New +$565K ﹤0.01% 1832
2023
Q3 		– Sell
-87,356
Closed -$1.58M – 2624
2023
Q2 		$1.58M Buy
87,356
+76,863
+733% +$1.82M ﹤0.01% 1454
2023
Q1 		$279K Sell
10,493
-22,454
-68% -$639K ﹤0.01% 2138
2022
Q4 		$637K Buy
32,947
+18,361
+126% +$384K ﹤0.01% 1799
2022
Q3 		$305K Buy
+14,586
New +$279K ﹤0.01% 2191

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Balyasny Asset Management's PLRX Position: Q3 2024 in Review

Balyasny Asset Management sold out of Pliant Therapeutics (PLRX) in Q3 2024, closing a stake of 31,910 shares — an estimated $343K sold.

Balyasny Asset Management first reported a position in PLRX in Q3 2022 and held it in 6 quarters. The position peaked at $1.58M in Q2 2023. 151 funds tracked by Wall St. Rank hold PLRX as of Q3 2024.

  • Balyasny Asset Management reported no remaining Pliant Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 31,910 Pliant Therapeutics shares in Q3 2024, an estimated $343K.
  • Balyasny Asset Management first reported a position in Pliant Therapeutics in Q3 2022 and held it in 6 quarters.
  • Balyasny Asset Management's Pliant Therapeutics position peaked at $1.58M in Q2 2023.
  • 151 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.